Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib in ALK+ or METex14 Advanced Solid Tumors (Excluding Lung)
NCT06762327Phase 2Not yet recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of ensartinib in solid tumor, sponsored by Nanjing First Hospital. Primary endpoints: Progression-Free Survival at 2 years and Overall Response Rate at 1 year. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
ensartinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06762327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06762327.